Clinical trial
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Study timeline
Study start (actual)2016-07-08Date precision: day
Registry last updated2025-10-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neoplasmsunresolved
Interventions
TSR-022DRUG
NivolumabDRUG · verified · RxNorm: nivolumab
TSR-042DRUG
TSR-033DRUG
DocetaxelDRUG · verified · RxNorm: docetaxel
PemetrexedDRUG · verified · RxNorm: pemetrexed
CisplatinDRUG · verified · RxNorm: cisplatin
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
Tesaro, Inc.lead sponsor
Mapped research locations
MadridSpain5SeoulSouth Korea4St LouisMissouri, United States3BarcelonaSpain3Los AngelesCalifornia, United States2AuroraColorado, United States2TucsonArizona, United States2ValenciaSpain2New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1ChicagoIllinois, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02817633 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.